Search

Your search keyword '"Anker, S D"' showing total 365 results

Search Constraints

Start Over You searched for: Author "Anker, S D" Remove constraint Author: "Anker, S D"
365 results on '"Anker, S D"'

Search Results

1. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

2. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines

4. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management

7. In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor

8. Impact of atrial flow regulator implantation on survival in patients with heart failure with reduced and preserved ejection fraction: a post-hoc analysis of the PRELIEVE study

9. Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial

11. Multicomponent intervention to prevent mobility disability in frail older adults:randomised controlled trial (SPRINTT project)

12. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)

13. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

14. Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry

16. The association between iron deficiency and outcomes: a secondary analysis of the intravenous iron therapy to treat iron deficiency anaemia in patients undergoing major abdominal surgery (PREVENTT) trial.

17. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

18. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

19. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

20. The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans

21. Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (Clinical Research in Cardiology, (2020), 109, 3, (331-338), 10.1007/s00392-019-01513-y)

22. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines

25. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

27. Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure (an update on the sodium–glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

28. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

29. WELCOME ADDRESS

30. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

33. Tumour biomarkers: association with heart failure outcomes

35. ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference

37. Effects of serelaxin in patients with acute heart failure

41. Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

42. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

43. Sarcopenia: A Time for Action. An SCWD Position Paper

44. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

49. Novel endotypes in heart failure: effects on guideline-directed medical therapy

50. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Catalog

Books, media, physical & digital resources